Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 16,449,204 shares, a decrease of 12.3% from the January 15th total of 18,757,451 shares. Approximately 8.2% of the shares of the stock are sold short. Based on an average daily volume of 2,763,492 shares, the days-to-cover ratio is presently 6.0 days.
NASDAQ:ENDP opened at $10.40 on Tuesday. Endo International has a 52 week low of $5.27 and a 52 week high of $18.50. The firm has a market capitalization of $2.27 billion, a PE ratio of 2.71, a PEG ratio of 3.80 and a beta of 1.28.
ENDP has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price objective on shares of Endo International from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, October 19th. ValuEngine cut shares of Endo International from a “hold” rating to a “sell” rating in a research report on Thursday, November 8th. Cowen reiterated a “hold” rating and set a $9.00 price objective on shares of Endo International in a research report on Friday, November 9th. Canaccord Genuity upgraded shares of Endo International from a “hold” rating to a “buy” rating and upped their price objective for the stock from $16.00 to $20.00 in a research report on Friday, November 9th. Finally, Mizuho decreased their price target on shares of Endo International to $15.00 and set a “neutral” rating for the company in a research report on Monday, November 26th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have issued a buy rating to the company’s stock. Endo International presently has a consensus rating of “Hold” and a consensus price target of $15.73.
In related news, Director William P. Montague sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $11.41, for a total transaction of $114,100.00. Following the completion of the transaction, the director now directly owns 64,888 shares in the company, valued at approximately $740,372.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.80% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the company. LS Investment Advisors LLC bought a new stake in shares of Endo International in the 4th quarter valued at $59,000. Oregon Public Employees Retirement Fund bought a new stake in shares of Endo International in the 4th quarter valued at $76,000. First Quadrant L P CA bought a new stake in shares of Endo International in the 4th quarter valued at $92,000. James Investment Research Inc. boosted its stake in shares of Endo International by 594.9% in the 3rd quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock valued at $184,000 after purchasing an additional 9,370 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new stake in shares of Endo International in the 3rd quarter valued at $202,000. 97.03% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thestockobserver.com/2019/02/12/endo-international-plc-endp-short-interest-down-12-3-in-january.html.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: No Load Funds
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.